Real-world studies have confirmed these results: a 2025 study published in Diabetes, Obesity and Metabolism found tirzepatide was associated with greater weight loss over 6 months than semaglutide in patients without diabetes, consistent with the trial data
By Steve Blechman BREAKING NEWS
Abstract Purpose Current management of type 2 diabetes mellitus and obesity increasingly includes treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs)
[61], LBPs were used as an adjuvant to lymphokine-activated killer (LAK) cells and IL-2 therapy in patients with various cancers, including malignant melanoma, lung cancer, renal cell carcinoma, and colorectal carcinoma
Many studies have supported the involvement of SCFAs, Bile acids, and Trimethylamine N-Oxide (TMAO) in CVD